文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

兰地洛尔与比索洛尔透皮贴剂治疗脓毒症相关心动过速的疗效比较:一项回顾性队列研究

Comparative efficacy of landiolol and bisoprolol transdermal patch in patients with sepsis-related tachycardia: a retrospective cohort study.
PubMed 文献 · J Intensive Care · 2026-08-05
一句话结论在脓毒症相关心动过速患者中,兰地洛尔与比索洛尔透皮贴剂在24小时心率控制上总体相当,但脓毒性休克亚组使用兰地洛尔的心率控制率更高。

本研究为多中心回顾性队列研究,纳入日本ICU数据库中2014年1月至2026年3月收治的成人脓毒症相关心动过速(HR≥100 bpm)患者,比较静脉兰地洛尔与比索洛尔透皮贴剂的疗效与安全性,并以1:1倾向性评分匹配调整基线差异。匹配后共分析950例(每组475例)。总体人群中24小时心率控制(60-94 bpm)比例无差异(兰地洛尔56% vs 比索洛尔54%,p=0.561);脓毒性休克亚组中兰地洛尔心率控制率更高(65% vs 53%,p=0.046)。两组院内死亡率、心动过缓发生率及24小时去甲肾上腺素等效剂量增加比例相当,兰地洛尔降心率更快。

要点

  • 总体脓毒症相关心动过速患者中,兰地洛尔与比索洛尔透皮贴剂24小时心率控制率相当(56% vs 54%,p=0.561)。
  • 脓毒性休克亚组中兰地洛尔24小时心率控制率高于比索洛尔透皮贴剂(65% vs 53%,p=0.046)。
  • 两组院内死亡率(5.1% vs 8.0%,p=0.088)、心动过缓(3.8% vs 5.9%,p=0.174)及24小时去甲肾上腺素等效剂量增加比例(16% vs 13%,p=0.170)均无统计学差异。
  • 兰地洛尔降心率更迅速,比索洛尔透皮贴剂降心率较温和。
  • 两种药物对死亡率的影响尚不明确,需进一步研究。

适用人群与场景

  • 成人脓毒症相关心动过速(心率≥100 bpm)患者,收治于参与日本ICU数据库的ICU(2014年1月至2026年3月)。
  • 脓毒性休克亚组为文中单独分析的人群。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 脓毒症相关心动过速定义:心率≥100 bpm。
  • 心率控制目标:60-94 bpm,评估时点为24小时。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药频次与目标值(仅提及静脉兰地洛尔与比索洛尔透皮贴剂两种给药方式)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究;倾向性评分1:1匹配后分析950例(每组475例)。
  • 主要终点:总体人群24小时心率控制(60-94 bpm)比例兰地洛尔56% vs 比索洛尔54%(p=0.561)。
  • 脓毒性休克亚组24小时心率控制率兰地洛尔65% vs 比索洛尔53%(p=0.046)。
  • 次要终点:院内死亡率5.1% vs 8.0%(p=0.088);心动过缓3.8% vs 5.9%(p=0.174);24小时去甲肾上腺素等效剂量增加比例16% vs 13%(p=0.170);兰地洛尔降心率更迅速。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究(非随机、观察性设计)。
  • 局限:回顾性设计存在残余混杂可能;死亡率差异未达统计学显著,作者指出对死亡率影响尚不明确,需进一步研究。

对床旁实践的改变

  • 在脓毒症相关心动过速总体人群中,两种药物24小时心率控制效果相当,可依据临床情境选择。
  • 脓毒性休克合并心动过速患者中,兰地洛尔可能更有利于24小时心率达标(65% vs 53%)。
  • 需要快速降心率时可优先考虑兰地洛尔(起效更迅速);比索洛尔透皮贴剂降心率较温和。
  • 原文未提供剂量方案,不能据此推断具体用药剂量。
  • mortality 影响不明确,不应以降低死亡率为目的选择药物。

指南或共识出处

  • 原文未提及具体指南或共识名称;研究数据来源于日本ICU数据库。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Tachycardia is common in sepsis and is associated with poor outcomes. β-blockers have been used for heart rate (HR) control, but comparative evidence between short- and long-acting agents remains limited. The aim of this study was to compare the efficacy and safety of intravenous landiolol and a bisoprolol transdermal patch in patients with sepsis-related tachycardia.

METHODS: This multicenter retrospective cohort study included adult patients with sepsis-related tachycardia (HR ≥ 100 bpm) treated with landiolol or a bisoprolol transdermal patch at intensive care units (ICUs) participating in a Japanese ICU database, from January 2014 to March 2026. Propensity score matching (PSM) at a 1:1 ratio was performed to adjust for baseline differences between groups. The primary outcome was the proportion of patients who achieved HR control (60-94 bpm) at 24 h. The secondary outcomes included in-hospital mortality, bradycardia incidence, the proportion requiring increased norepinephrine-equivalent doses at 24 h, and trends in HR and mean arterial pressure (MAP) over 24 h.

RESULTS: After PSM, data from 950 patients were analyzed (n = 475 in each group). HR control at 24 h did not differ between the two groups (landiolol: 56% vs. bisoprolol: 54%, p = 0.561) in overall sepsis patients. In the subgroup of patients with septic shock, HR control at 24 h was achieved more frequently with landiolol than with bisoprolol (65 vs. 53%; p = 0.046). In-hospital mortality was 5.1% in the landiolol group and 8.0% in the bisoprolol group (p = 0.088). Bradycardia incidence (3.8 vs. 5.9%, p = 0.174) and the proportion of patients requiring increased norepinephrine-equivalent doses at 24 h (16 vs. 13%, p = 0.170) were comparable between the two groups. Landiolol achieved a more rapid HR reduction, whereas bisoprolol induced a moderate decrease in HR.

CONCLUSIONS: Landiolol and the bisoprolol transdermal patch achieved comparable 24-h HR control in the overall cohort of sepsis patients with tachycardia. A higher rate of HR control with landiolol was observed in patients with septic shock. The effect of these agents on mortality remains unclear, and further studies are warranted.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Murao S, Yoshimura J, Umemura Y, et al. Comparative efficacy of landiolol and bisoprolol transdermal patch in patients with sepsis-related tachycardia: a retrospective cohort study. J Intensive Care. 2026. PMID: 42687192. doi:10.1186/s40560-026-00924-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。